{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:52:21Z","timestamp":1783691541481,"version":"3.55.0"},"reference-count":26,"publisher":"Association for Research in Vision and Ophthalmology (ARVO)","issue":"2","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trans. Vis. Sci. Tech."],"DOI":"10.1167\/tvst.14.2.21","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T11:32:17Z","timestamp":1740051137000},"page":"21","source":"Crossref","is-referenced-by-count":4,"title":["Effect of Combination Use of Aqueous Humor Secretion Inhibitor Eye Drops on Aflibercept Level: A Preliminary Analysis"],"prefix":"10.1167","volume":"14","author":[{"given":"Satoru","family":"Inoda","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Jichi Medical University, Shimotsuke-shi, Tochigi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Jichi Medical University, Shimotsuke-shi, Tochigi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Jichi Medical University, Shimotsuke-shi, Tochigi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuto","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Jichi Medical University, Shimotsuke-shi, Tochigi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Jichi Medical University, Shimotsuke-shi, Tochigi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Jichi Medical University, Shimotsuke-shi, Tochigi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiro","family":"Fujino","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Japan Community Healthcare Organization Tokyo Shinjuku Medical Center, Shinjuku-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Aizawa","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Pharmacology, Jichi Medical University, Tochigi, Japan"},{"name":"Clinical Pharmacology Center, Jichi Medical University Hospital, Tochigi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Kawashima","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Jichi Medical University, Shimotsuke-shi, Tochigi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Yanagi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Micro-Technology, Yokohama City University, Yokohama, Japan"},{"name":"Retina Research Group, Singapore Eye Research Institute, Singapore Eye-ACP, Duke-NUS Medical School, National University of Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"bib1","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","article-title":"HAWK and HARRIER: Ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration","volume":"128","author":"Dugel","year":"2021","journal-title":"Ophthalmology"},{"key":"bib2","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","article-title":"TENAYA and LUCERNE: Two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2","volume":"131","author":"Khanani","year":"2024","journal-title":"Ophthalmology"},{"key":"bib3","first-page":"11","article-title":"Pharmacokinetics of intravitreal anti-VEGF drugs in age-related macular degeneration","author":"Garc\u00eda-Quintanilla","year":"2019","journal-title":"Pharmaceutics"},{"key":"bib4","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.preteyeres.2016.12.001","article-title":"Pharmacokinetic aspects of retinal drug delivery","volume":"57","author":"Del Amo","year":"2017","journal-title":"Prog Retin Eye Res"},{"key":"bib5","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1016\/j.ophtha.2007.09.012","article-title":"Pharmacokinetics of intravitreal ranibizumab (Lucentis)","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"key":"bib6","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.ajo.2008.05.036","article-title":"Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans","volume":"146","author":"Krohne","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"bib7","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ajo.2012.03.047","article-title":"Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans","volume":"154","author":"Krohne","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"bib8","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1080\/03007995.2019.1595553","article-title":"Topical medical therapy and ocular perfusion pressure in open angle glaucoma: a systematic review and meta-analysis","volume":"35","author":"Rennie","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"bib9","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.exer.2008.10.018","article-title":"Measurement of aqueous humor flow","volume":"88","author":"McLaren","year":"2009","journal-title":"Exp Eye Res"},{"key":"bib10","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1136\/bjo.2007.134874","article-title":"Predicted biological activity of intravitreal VEGF Trap","volume":"92","author":"Stewart","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"bib11","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1136\/bjophthalmol-2014-305252","article-title":"Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD","volume":"98","author":"Avery","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"bib12","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1097\/IAE.0000000000002710","article-title":"Correspondence","volume":"40","author":"Caruso","year":"2020","journal-title":"Retina"},{"key":"bib13","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1097\/IAE.0000000000002566","article-title":"Pharmacokinetic study of intravitreal aflibercept in humans with neovascular age-related macular degeneration","volume":"40","author":"Do","year":"2020","journal-title":"Retina"},{"key":"bib14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1089\/jop.2022.0146","article-title":"Ocular pharmacokinetic properties of intravitreally injected aflibercept in rabbits after using brinzolamide\/timolol eye drops","volume":"39","author":"Zhou","year":"2023","journal-title":"J Ocul Pharmacol Ther"},{"key":"bib15","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ejpb.2015.01.003","article-title":"Intravitreal clearance and volume of distribution of compounds in rabbits: In silico prediction and pharmacokinetic simulations for drug development","volume":"95","author":"del Amo","year":"2015","journal-title":"Eur J Pharm Biopharm"},{"key":"bib16","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/eye.2014.329","article-title":"Intraocular pharmacokinetics of intravitreal vascular endothelial growth factor-Trap in a rabbit model","volume":"29","author":"Park","year":"2015","journal-title":"Eye (Lond)"},{"key":"bib17","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10237-009-0159-0","article-title":"Mathematical model of flow in the vitreous humor induced by saccadic eye rotations: effect of geometry","volume":"9","author":"Repetto","year":"2010","journal-title":"Biomech Model Mechanobiol"},{"issue":"Suppl 1","key":"bib18","first-page":"281","article-title":"The vitreous model - a new in vitro test method simulating the vitreous body","volume":"57","author":"Loch","year":"2012","journal-title":"Biomed Tech (Berl)"},{"key":"bib19","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/jps.23808","article-title":"Simulation of drug distribution in the vitreous body after local drug application into intact vitreous body and in progress of posterior vitreous detachment","volume":"103","author":"Loch","year":"2014","journal-title":"J Pharm Sci"},{"key":"bib20","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1089\/108076801753162807","article-title":"Review: practical issues in intravitreal drug delivery","volume":"17","author":"Maurice","year":"2001","journal-title":"J Ocul Pharmacol Ther"},{"key":"bib21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11095-012-0847-9","article-title":"Retina-choroid-sclera permeability for ophthalmic drugs in the vitreous to blood direction: quantitative assessment","volume":"30","author":"Haghjou","year":"2013","journal-title":"Pharm Res"},{"key":"bib22","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1002\/jps.24480","article-title":"The PK-eye: a novel in vitro ocular flow model for use in preclinical drug development","volume":"104","author":"Awwad","year":"2015","journal-title":"J Pharm Sci"},{"key":"bib23","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ejpb.2017.12.019","article-title":"Antibody loaded collapsible hyaluronic acid hydrogels for intraocular delivery","volume":"124","author":"Egbu","year":"2018","journal-title":"Eur J Pharm Biopharm"},{"key":"bib24","doi-asserted-by":"publisher","first-page":"1700255","DOI":"10.1002\/mabi.201700255","article-title":"Comparative study of in situ loaded antibody and PEG-Fab NIPAAM gels","volume":"18","author":"Awwad","year":"2018","journal-title":"Macromol Biosci"},{"key":"bib25","doi-asserted-by":"publisher","first-page":"104993","DOI":"10.1016\/j.ejps.2019.104993","article-title":"In situ antibody-loaded hydrogel for intravitreal delivery","volume":"137","author":"Awwad","year":"2019","journal-title":"Eur J Pharm Sci"},{"key":"bib26","doi-asserted-by":"publisher","first-page":"12246","DOI":"10.1038\/s41598-021-91832-w","article-title":"Incidence of elevated intraocular pressure after intravitreal injection in Japanese patients with age-related macular degeneration","volume":"11","author":"Maruyama-Inoue","year":"2021","journal-title":"Sci Rep"}],"container-title":["Translational Vision Science & Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/tvst.arvojournals.org\/article.aspx?articleid=2802608","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:00:58Z","timestamp":1759330858000},"score":1,"resource":{"primary":{"URL":"https:\/\/tvst.arvojournals.org\/article.aspx?articleid=2802608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,3]]}},"URL":"https:\/\/doi.org\/10.1167\/tvst.14.2.21","relation":{},"ISSN":["2164-2591"],"issn-type":[{"value":"2164-2591","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,20]]}}}